1PANTAZIS P, EARLYJ A. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro [ J ]. Cancer Res, 1994,54 ( 3 ) : 771 - 776.
2HUX, BALANK V. Differential susceptibility to 9-nitrocamptothecin (9-NC)-induced apoptosis in clones derived from a human ovarian cancer cell line: possible implications in the treatment of ovarian cancer patients with 9-NC [ J ]. Anticancer Drugs, 2003,14 ( 6 ) : 427 - 436.
3PANTAZIS P, KOZIELSKI A J. Camptothecin derivatives induce re- gression of human ovarian carcinomas grown in nude mice and distinguish between nontumorigenic and tumorigenic cells in vitro [J]. Int J Cancer,1993,53(5) :863 -871.
4KOSHKINAN V, KLEINERMAN E S. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice[J]. Clin Cancer Res ,2000 ,6 ( 7 ) :2876 -2880.
5HAN Z, WYCHE J H. 9-Nitrecamptothecin is an effective drug for the treatment of human lung tumors: comparison of in vitro and in vivo studies[J]. Anti, cancer Res,2001,21(3B) :1823 - 1827.
6PANTAZI S P, EARLEJ A. Regression of human breast carcinoma tumors in immunodeticient mice treated with 9-nitrecamptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro[ J]. Cancer Res, 1993,53 (7) : 1577 - 1582.
7PANTAZI S P, MENDOZA J T. 9-Nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatie for human myelomonocytic leukemia lines in vitro [ J ]. Eur J Haematol, 1993,50 (2) :81 - 89.
8KNIGHT V, KOSHKINAN V. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice [ J]. Cancer Chemother Pharmacol,1999,44( 3 ) :177 - 186.
9AMORINO G P, HERCULESS K. active eamptothecin analog, Preclinical evaluation of the orally RFS-2000 ( 9-nitro-20 ( S )-camptothecin) as a radiation enhancer[ J]. Int J Radiat Oncol Biol Phys ,2000,47 ( 2 ) :503 - 509.
10SADAIEM R, DONIGER J. 9-nitrocamptothecin selectively inhibits human immunodeficiency virus type ireplication in freshly infected parental but not 9-nitrocamptothecin-resistant U937 monocytoid cells [ J]. AIDS Res Hum Retroviruses, 1999,15 ( 3 ) :239 - 245.
2Ikegami T,Ha L,Arimori K,et al.Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea[J].Cancer Res,2002,62(1):179-87.
3Ulukan HSwaan PW.Camptothecins:a review of their chemotherapeutic potential[J].Drugs,2002,62(14):2039-57.
4Oguma T.Antitumor drugs possessing topoisomerase I inhibition:applicable separation methods[J].J Chromatogr B Biomed Sci Appl,2001,764(1-2):49-58.
5Laco GS,Collins JR,Luke BT,et al.Human topoisomerase I inhibition:docking camptothecin and derivatives into a structure-based active site model[J].Biochemistry,2002,41(5):1428-35.
6Sanchez-Alcazar JA,Ault JG,Khodjakov A,et al.Increased mitochondrial cytochrome c levels and mitochondrial hyperpolarization precede camptothecin-induced apoptosis in Jurkat cells[J].Cell Death Differ,2000,7(11):1090-100.
7Shao RG,Cao CX,Nieves-Neira W,et al.Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells[J].Oncogene,2001,20(15):1852-9.
8Shibakura M,Niiya K,Kiguchi T,et al.Camptothecin induces urokinase-type plasminogen activator gene-expression in human RC-K8 malignant lymphoma and H69 small cell lung cancer cells[J].Acta Med Okayama,2002,56(5):223-7.
9Lee S,Lee HS,Baek M,et al.MAPK signaling is involved in camptothecin-induced cell death[J].Mol Cells,2002,14(3):348-54.
10Costa-Pereira AP,McKenna SL,Cotter TG.Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis[J].Br J Cancer,2000,82(11):1827-34.
1Pommier Y, Leo E, Zhang H, et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs [ J ]. Chem Biol, 2010, 17(5) :421433.
2Tomieic MT, Kaina B. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptotheein-like topoi- somerase I inhibitors[ J ]. Biochim Biophys, 2013, 1835 ( 1 ) : 11-27.
3Baker NM, Rajan R, Mondrag6n A. Structural studies of type ] topoisomerases [ J]. Nucleic Acids Res, 2009, 37 ( 3 ) :693-701.
4Champoux JJ. DNA topoisomerases : structure, function, and mech- anism[J]. Annu Rev Biochem, 2001, 70:369-413.
5Soepenberg O, Sparreboom A, Verweij J. Clinical studies of camptothecin and derivatives [ J ]. Alkaloids Chem Biol, 2003, 60:1-50.
6Ghilarov DA, Shkundina IS. DNA topoisomerases and their func- tions in a cell[J]. Mol Biol(Mosk), 2012, 46(1 ) :52-63.
7Pommier Y. DNA topoisomerase I inhibitors: chemistry, biolo- gy, and interracial inhibition [ J ]. Chem Rev, 2009, 109 (7) : 2894-2902.
8Zhang H, Meng LH, Pommier Y. Mitoehondrial topoisomerases and alternative splicing of the human TOP1 nat gene [J]. Bio- chimie, 2007, 89(4) :474-481.
9Wu N, Wu XW, Agama K, et al. A novel DNA topoisomerase I inhibitor with different mechanism from camptotheein induces G2/M phase cell cycle arrest to K562 cells [ J]. Biochemistry, 2010, 49(47) :10131-10136.
10Pommier Y. Topoisomerase I inhibitors : eamptotheeins and be- yond[J]. Nat Rev Cancer, 2006, 6(10) :789-802.
